Nectero Medical is a technology company.
Nectero Medical has raised $96.0M across 1 funding round.
Nectero Medical has raised $96.0M in total across 1 funding round.
Nectero Medical has raised $96.0M in total across 1 funding round.
Nectero Medical's investors include Alumni Ventures, Amity Ventures, Ehukai Investments, Norwest Venture Partners, Origin Ventures, S3 Ventures, Trucks Venture Capital.
Nectero Medical is a clinical-stage biotechnology and medical technology company developing the Nectero Endovascular Aneurysm Stabilization Treatment (EAST®) System, a minimally invasive, single-dose endovascular therapy for small to medium-sized infrarenal abdominal aortic aneurysms (AAAs) measuring 3.5–5.0 cm in diameter[1][2][4]. The system uses a dual-balloon delivery catheter to locally apply pentagalloylglucose (PGG), which binds to elastin and collagen in the aneurysmal wall to strengthen it, slow growth, and reduce rupture risk without leaving a permanent implant[1][2][4]. It targets patients under active surveillance who are not yet surgical candidates, addressing a critical unmet need where over 15,000 U.S. patients die annually from ruptured AAAs[3]. The company, based in Tempe, Arizona, has raised $115.5M in funding, including a $96M Series D in 2024, and is enrolling in the pivotal Phase II/III stAAAble trial after receiving FDA Fast Track and Breakthrough Therapy designations in 2023[1][2][4].
Growth momentum is strong, with awards like the 2024 AZBio Fast Lane Award, ongoing trial initiation, and plans for FDA New Drug Application submission[1][4].
Founded in 2017 in Tempe, Arizona, Nectero Medical emerged to tackle the lack of non-surgical options for early to mid-sized AAAs, where patients face lifelong surveillance or high-risk invasive procedures[1][3]. The idea stemmed from the need for a simple, catheter-based treatment to stabilize aneurysms before rupture, led by a multidisciplinary team with deep expertise in vascular interventions and device development[1][5]. Key early milestones include positive Phase 1 safety study results, a $19.5M Series C financing in an earlier round led by Boston Scientific, and FDA Breakthrough Therapy designation in 2023, paving the way for the stAAAble trial launch in 2024[1][3][4]. Leadership under President and CEO Jack Springer, alongside advisers like Venkatesh Ramaiah, MD, has driven progress, with recent board additions like Zack Scott, MD, and Alan Davis, MD, from Series D investors[4][5].
Nectero rides the wave of advances in endovascular therapies and tissue stabilization biotech, targeting the growing AAA market amid an aging population and rising aneurysm prevalence[3]. Timing is ideal post-FDA designations and trial initiation, aligning with demand for less invasive alternatives to open surgery or EVAR, which carry long-term risks[1][3][4]. Favorable market forces include investor enthusiasm (e.g., $96M Series D) and recognition like AZBio awards, positioning Nectero to influence vascular medtech by enabling earlier intervention and reducing rupture-related deaths[1][4]. It contributes to the ecosystem by partnering with firms like Boston Scientific and advancing clinical data that could reshape AAA management standards[3][4].
Nectero is poised for commercialization post-stAAAble trial data, with NDA submission targeted soon after completion, potentially transforming AAA care by 2026–2027[4]. Trends like biotech-regulatory fast-tracking and endovascular innovation will propel it, especially if trial success validates stabilization claims. Its influence may expand to other aneurysmal diseases, amplifying impact in a high-unmet-need vascular space—echoing its origins as a pioneer against aneurysm progression[1][3].
Nectero Medical has raised $96.0M across 1 funding round. Most recently, it raised $96.0M Series D in April 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2024 | $96.0M Series D | Alumni Ventures, Amity Ventures, Ehukai Investments, Norwest Venture Partners, Origin Ventures, S3 Ventures, Trucks Venture Capital |